N-Oleoyl-PE大豆萃取物

PhosphoLean® N-Oleoyl-PE + EGCG (NOPE + EGCG) is the "next generation" nutritional supplement compound for advanced appetite control and weight management. PhosphoLean® NOPE + EGCG is a safe, natural, and effective nutritional supplement compound that can help individuals manage their ideal body weight.

Overweightness and obesity are increasing at alarming rates, and seemingly in all age groups except, perhaps, the elderly. The toll that obesity, in particular, places on us from both family and social standpoints is far reaching, especially considering management of health costs and overall illness commonly associated with obesity.

Recent research involving the manipulation of appetite has shown that suppressing appetite and thus reducing the intake of food is an effective means to controlling both energy balance and body weight. Since appetite suppression is a major controlling point for energy (food) intake, managing appetite is crucial in controlling healthy body weight, especially when combined with health conscious lifestyle choices that include attention to proper food intake, dietary supplementation, and exercise.

Under the severe stress levels experienced during dieting, studies have shown that PhosphoLean® NOPE + EGCG can effectively help individuals manage the daily stress of their calorie reduced diets and help them stay on diets for longer periods of time. Only this will lead to long-term diet success.

• Health Benefits
  • Helps individuals stay on their stressful low calorie diets to achieve weight loss goals.
  • Fights "Diet Dropout".
  • Suppresses appetite so food and calorie intake can be reduced.
  • Reduces diet stress and minimizes depression, that is normally felt when dieting.
  • Reduces binge eating and between meal eating.
  • Improves insulin resistance and overall physiology.
• Science Information
  PhosphoLean® N-Oleoyl-PE + EGCG (NOPE + EGCG) is a proprietary phosphobioflavonic complex of N-oleoyl-phosphatidyl-ethanolamine (NOPE), which contains oleoyl ethanolamine (OEA) bound to phosphatidylethanolamine (PE), a naturally occurring phospholipid found in animal and vegetable foods, and epigallocatechin gallate (EGCG), from standardized green tea extract.

  After oral administration, PhosphoLean® NOPE + EGCG is gastro-protected in the stomach, and in the intestinal tract, OEA, a newly discovered lipid mediator involved in the regulation of feeding, is enzymatically liberated.

  Recent research has shown that OEA binds to a cell receptor class called peroxisome-proliferator-activated receptor-alpha (PPAR-alpha) found in the intestinal tract. These receptors, when activated, are responsible for signaling the brain center to decrease appetite and hence to reduce both food intake and body weight gain.

  Recent findings from a large study involving 138 obese and overweight men and women on an eight week low calorie diet, conducted by Dr. Mariangela Rondanelli at the University of Pavia in Italy, showed that subjects on PhosphoLean® NOPE + EGCG experienced only a 6% drop out rate vs. a 27% drop put rate for the placebo group.

  In addition, sensation of appetite, depressive symptoms, and binge eating severity scores were statistically much more favorable for the PhosphoLean® NOPE + EGCG group. Finally, insulin resistance and blood lipid markers were also statistically more favorable for this active group as well.

  There is an increasing demand for pharmaceutical treatment for overweightness and obesity - lifestyle-associated conditions. Decreasing nutrient absorption, inhibition of appetite, and increasing thermogenesis are all currently being considered as possible pharmacological methods of treatment, while appetite suppression, through discovery of special nutrients and newly discovered metabolic pathways, is now opening new science doors.

  The EGCG polyphenols in PhosphoLean® NOPE + EGCG act synergistically with OEA via sympathetic activation of thermogenesis and increased fat oxidation, thus enhancing its weight management effects.
• Applications
  • Dietary supplements.
  • Functional foods.
  • Functional beverages.
  • Medical foods.

  The ingredient compound PhosphoLean® N-Oleoyl-PE + EGCG (NOPE + EGCG) has particular application in weight management and in men's and women's healthy lifestyle supplement products. The scientific support for the cell-signaling mechanism of PhosphoLean® NOPE + EGCG to "turn off the hunger switch" is well acknowledged and clinical work in this arena is ongoing. Based on continued trends in society, the future for PhosphoLean® NOPE + EGCG in weight management formulations looks very, very bright.

  
  
• 臨床論文 :

  The effect of a dietary supplement (N-oleyl-phosphatidyl-ethanolamine and epigallocatechin gallate) on dietary compliance and body fat loss in adults who are overweight: A double-blind, randomized control trial

  Gerald T Mangine,1 Adam M Gonzalez,1 Adam J Wells,1 William P McCormack,1 Maren S Fragala,1 Jeffrey R Stout,1and Jay R Hoffman1

  
  

  Abstract

  Background

  A dietary supplement containing a blend of 170mg of N-oleyl-phosphatidylethanolamine (NOPE) and 100mg of epigallocatechin-3-gallate (EGCG) has been shown to improve compliance to low caloric diets. Considering the cost of dietary ingredients, many manufacturers attempt to determine the lowest efficacious dose. Thus, the purpose of this study was to evaluate the efficacy of 8-weeks of supplementation with a daily intake of 120mg of NOPE and 105mg of EGCG in conjunction with a low caloric diet and regular, moderate exercise on dietary compliance in healthy, overweight adults. An additional purpose was to examine the effect of this supplement/diet/exercise paradigm on changes in body composition, sensation of appetite, mood and severity of binge eating.

  Methods

  Fifty healthy, overweight (BMI>25m·kg2) men (15) and women (35) (SUP; n=25; 32.7±13.75 y; BMI=33.4±6.2; PLA; n=25, 34.3±12.7years; BMI=33.2±6.8) were recruited for a double-blind, placebo controlled study. Each volunteer was randomly assigned to either the supplement (SUP; n=25) or placebo group (PLA; n=25). Based upon a self-reported 3-day dietary recall all volunteers were recommended a 500kcal or 30% (maximum of 1000kcal) reduction in caloric intake. Volunteers were also encouraged to exercise 30minutes per day, three times per week.

  Results

  Subjects in SUP were significantly more compliant (x2=3.86, p=0.049) in maintaining a low caloric diet at week 4, but this was not able to be maintained through the 8-week study. In addition, a significant difference in mood, feelings of fatigue and confusion were noted between the groups at week 4, but again not maintained by week 8 where only feelings of tension were improved. No differences between groups (p>0.05) were observed for body mass, body composition, feelings of hunger, and binge eating after eight weeks.

  Conclusion

  Supplementing with a combination of 120mg of NOPE and 105mg of EGCG does appear to enhance compliance to a low caloric diet and improve mood for 4 –weeks, but loses its effectiveness by week 8.

  Keywords: Dietary Adherence, Appetite, Obesity, Green Tea Extract

  
  

  Go to:

  Introduction

  Excess body weight is a major health problem in the United States. More than 60% of adult Americans are classified as being overweight [1] and approximately 34% as obese [2]. Excess body fat increases the risk for several debilitating and potentially fatal diseases [3-7]. Research indicates that body mass index, waist circumference, and body fat percentages can be significantly reduced through a combination of diet and exercise, in comparison to diet alone [8,9]. However, a major determinant for success during a weight loss regimen is an individual’s ability to adhere to a low calorie diet for an extended duration [10,11]. Although caloric restriction is an effective method of losing body weight and body fat, it becomes more challenging if adherence to the diet cannot be maintained [11]. In response to this need the pharmaceutical industry developed a number of prescription medications to enhance the success of weight loss programs. Although there has been varying degrees of success [12], a high incidence of adverse events has shifted research to the development of non-prescription interventions [13-15]. Non-prescription weight loss supplements focus on several different mechanisms of action including enhancing satiety, thermo genesis, and the inhibition of enzymes that metabolize both carbohydrates and fats [16]. However, the efficacy and safety of these interventions has not been fully elucidated.

  N-oleoyl-phophatidyl-ethanolamine (NOPE) and epigallocatechin gallate (EGCG) are naturally occurring nutritional ingredients, whose biological properties may enhance compliance to a reduced calorie diet [17-28]. NOPE, a naturally occurring phospholipid found in animal and vegetable foods, is hydrolyzed into N-oleyl-ethanolamide (NOE) and phosphatidic acid when consumed [17]. Its proposed mechanism of action is related to NOE’s role in inhibiting the effect of anandamide (N-arachidonyl-ethanolamine), an agonist of both peripheral and central cannabinoid type 1 receptors (CB1) whose activation leads to an increase in appetite and, consequently, an intake of food [18]. In rats, an intra-peritoneal injection of NOE has been shown to promote an anorexic effect through the activation of several intestinal receptors, which signal the brain center to reduce food intake [19,20]. EGCG, from standardized green tea extract, has been shown to stimulate weight [21,22] and fat loss [22,23] by inhibiting enzymes that contribute to the degradation of catecholamines [24,25], which stimulate lipolysis. In mice fed a high-fat diet, EGCG supplementation has been shown to attenuate gains in body mass, total body fat, and visceral fat [26]. Others have suggested that NOPE and EGCG by themselves may not be effective for weight loss [27,28], However, other investigators have demonstrated that a combination of these compounds may result in improved absorption of EGCG and prevent the rapid breakdown of NOPE, improving its availability [28].

  A recent study in humans reported that a combination of NOPE (170mg·day-1) and EGCG (100mg·day-1) resulted in greater low calorie dietary compliance, improved mood and satiation, as well as decreases in depressive symptoms compared to a placebo [17]. However, weight loss was similar between groups, suggesting body weight reductions were not directly related to the dietary supplement. Thus, the purpose of this study was to determine if a proprietary blend of NOPE and EGCG, using lower concentrations of NOPE than previously reported, in conjunction with regular exercise, could improve dietary compliance to a low caloric diet and result in positive body composition changes in healthy, overweight adults.

  
  

  Go to:

  Methods

  Subjects

  Fifty healthy adults (35 female, 15 male) volunteered to participate in an 8-week randomized, double-blind investigation. Following an explanation of all procedures, risks, and benefits associated with the experimental protocol, each volunteer gave his or her written informed consent to participate in this study. The research protocol was approved by the Institutional Review Board at the University of Central Florida. Inclusion criteria required participants to be between 18 – 59years of age, with a body mass index (BMI) greater than 25 but less than 40, and their daily energy intake to be at, or above their calculated dietary fuel requirement. Participants were randomly assigned to one of two groups. One group was provided the supplement (SUP; n=25; 17 females, 8 males; 32.7±13.7years; 93.3±19.5kg; BMI=33.4±6.2; 43.2±7.2% Body Fat) containing 120mg NOPE and 105mg of EGCG, and the second group was provided a placebo (PLA; n=25, 18 females, 7 males; 34.3±12.7years; 92.8±18.6kg; BMI=33.26±6.8; 44.0±6.8% Body Fat) containing an equivalent amount of rice flour.

  Study design

  The study protocol was 8-weeks in duration and included a total of 6 visits with the investigators that included an initial familiarization visit. If enrolled, the subject returned to the Human Performance Laboratory for baseline measures (WK0) and then every two weeks for follow-up assessments (WK2, WK4, Wk6, and WK8, respectively). During the initial familiarization session, an explanation of study procedures associated with the experimental protocol was provided to potential subjects. Upon giving his or her written informed consent to participate in the study, the subject was asked to complete a medical history questionnaire. In addition, the subject’s BMI was calculated and then checked to determine if the subject met the investigation’s inclusion criteria. If the subject was enrolled into the study, they were then instructed to complete a 3-day dietary recall, consisting of two weekdays and one weekend day, to determine daily caloric intake. The 3-day dietary recall was returned for analysis prior to baseline measurements, to determine if caloric intake met the study’s inclusion criteria. During each subsequent laboratory visit anthropometric measures and study questionnaires were completed. The study protocol is described in Figure ​Figure11.

  Figure 1

  
  
  

  

  Flowchart of study design.

  During the study subjects were recommended to maintain a regular exercise schedule that included at least 3days per week, for 30minutes per day at an intensity that that would elicit between 60 – 75% of the subject’s maximum heart rate. Volunteers were instructed to record their daily activity and provide these records to the investigators at each visit.

  Dietary analysis

  The 3-day dietary recall was analyzed using the Food Works 13 Nutritional Assessment Software (The Nutrition Company, Long Valley, NJ, USA) and average caloric intake was determined. Total Energy Expenditure (TEE) was determined by a formula previously published [29] and used to exclude individuals who did not meet the study’s inclusion criteria. Subject’s TEE was determined by age, height, weight, and reported physical activity. If the subject’s dietary recall indicated that their daily caloric intake was at or above the TEE, they were then recommended a diet that was 30% or 500kcal per day (whichever was greater) less than what they had been consuming. However, the maximum restriction did not exceed 1000kcal per day. The same investigator provided dietary recommendations for each subject. Compliance was measured as the ability to maintain the recommended hypo-caloric diet over the course of the 8-week investigation. Caloric intake was reevaluated at WK4 and WK8.

  Anthropometric measurements

  Anthropometric measurements for all participants were conducted in the following sequence: height (WK0 only) and body mass, body mass index (BMI), waist circumference, and Dual Energy X-Ray Absorptiometry (DEXA) measurements. Body mass (measured to the nearest 0.1kg) and height (measured to the nearest 0.01m) were determined using a Health-o-meter Professional (Patient Weighing Scale, Model 500 KL, Pelstar, Alsip, IL, USA). Measurements were performed with the participants standing barefoot, with feet together, in their normal daily attire. Body mass index (BMI) was calculated as measured weight divided by the square of measured height. Waist circumference was measured using techniques previously described [30] by the same investigator for each subject.

  Body composition was determined using whole body-dual energy x-ray absorptiometry (DEXA) scans (Prodigy™; Lunar Corporation, Madison, WI). Total body estimates of percent fat, fat and non-bone lean tissue was determined using company’s recommended procedures and supplied algorithms. Quality assurance was assessed by daily calibrations and was performed prior to all scans using a calibration block provided by the manufacturer.

  Abdominal fat was determined as previously described [31]. Briefly, a quadrilateral box was manually drawn around the L1-L4 region of interest (abdomen) bounded inferiorly by the horizontal line identifying the L4/L5 vertebral space and superiorly by the horizontal line identifying the T12/L1 vertebral space. Scans were displayed with an adjustment of the gray scale, so that all of the soft tissue in the designated area was included.

  Questionnaires

  The Hunger and Satiety Scale (HSS) [32], Profile of Mood States (POMS) [33], and Binge Eating Scale (BES) [34] were administered during each visit beginning WK0. The HSS was assessed numerically, using a scoring system graded from 0, to represent ravenous hunger, to plus 10, which represents feeling stuffed or overfull. Volunteers were shown a scale with ten gradations and asked to indicate how they felt in respect to hunger or satiety by circling the appropriate place along the scale. The scale also consisted of phrases describing the various degrees of hunger or satiety, but volunteers were free to choose any point along the scale [32]. The POMS consists of 58 words or phrases in a Likert format questionnaire which provides measures of specific mood states. It provides measures of tension, depression, anger, vigor, fatigue and confusion. A total mood score is computed by subtracting vigor from the sum of the five other negative measures and adding 100 to avoid a negative result [33]. The BES, which has been shown to be a valid and reliable measure of classifying binge eaters, included sixteen items measuring the severity of binge eating. It examines both behavioral manifestations (eating large amounts of foods) and feeling/cognition during a binge episode (loss of control, guilt, and fear of being unable to stop eating). Participants scoring 17 or lower on the BES were classified as non-binge eaters, those with a score of 18 – 26 as moderate binge eaters, and those scoring 27 or higher as severe binge eaters [34]. All questionnaires were performed under controlled conditions (a quiet room alone with the investigator). During all test administrations participants were asked to describe their feelings upon how they were feeling at the moment.

  Supplement

  The supplement, marketed as PhosphoLean™ (Chemi Nutra, White Bear Lake, MN), contained a proprietary blend of NOPE, a naturally occurring phospholipid found in soy, and EGCG, from standardized green tea extract. Each capsule contained 40mg of NOPE, 35mg of EGCG and 25mg of mixed phospholipids. The placebo contained an equal amount of rice flour. Participants were instructed to ingest 300mg per day (three capsules, 100mg per capsule) of SUP or PLA (100mg rice flour per capsule); one capsule was consumed 60minutes prior to lunch and two capsules 60minutes prior to dinner.

  Statistical analysis

  The efficacy of the supplement was determined by calculating the change ( score) from WK0 to each measuring point (WK2, WK4, WK6 and WK8). Due to participant drop out or removal, the number of participants per visit was reduced. To account for the different sample sizes at each time point independent t-tests using the Bonferroni method to correct for multiple assessments was employed to compare group differences. Chi-square analysis was used to analyze compliance at WK4 and WK8. A criterion alpha level of p≤0.05 was used to determine statistical significance prior to Bonferroni correction.

  Go to:

  Results

  Thirty-two (SUP: 11 females, 5 males; PLA: 12 females, 4 males) of the original fifty volunteers completed the study. Seven participants (SUP=4, PLA=3) dropped out by WK2, Four additional participants (SUP=2, PLA=2) dropped out after WK4, and five participants (SUP=3, PLA=2) were deemed to be non-adherent. Non-adherence was defined as participants who did not take a minimum of 70% of the product or who did not complete their final measurements. Their data were not included in any of the analyses. Of the remaining two participants, one in the SUP group withdrew from the study (prior to WK2) when she was diagnosed with hypothyroidism, which was not related to the supplement. The other subject, in the placebo group, experienced blurry vision, headache, increased appetite, shakiness, and disrupted alertness prior to WK2. Analysis of dietary recalls indicated greater compliance (x2=3.86, p=0.049) to the low caloric diet in SUP (57.14%) compared to PLA (42.86%) at WK4. However, no differences (x2=0.000, p=1.000) in dietary compliance were noted between the groups by WK8. When comparing caloric intake between groups, no difference from the change from WK0 were seen between SUP (-889±662kcal and -911±871kcal) and PLA (-619±1127kcal and -718±1337kcal) at WK4 and WK8, respectively.

  Analysis of the participants self-reported exercise habit revealed no significant differences (p=0.577) in weekly training frequency between PLA (p=0.577; 2.7±1.0days per week) and SUP (3.0±1.6days per week) or in minutes per workout (p=0.884; 55.6±25.5min versus 54.3±15.5, respectively). No significant differences were seen between the groups in changes of body mass at any time point (see Figure ​Figure2).2). Similarly, no significant differences were noted in the change in % body fat (-0.4±2.0% versus -0.1±2.8%), lean body mass (-0.4±1.6kg versus -0.2±1.6kg), waist circumference (-3.7±1.6cm versus -0.3±7.8cm) and central adiposity (-0.3±1.4kg versus -0.3±0.8kg) between PLA and SUP, respectively.

  Figure 2

  
  
  

  

  Changes from baseline in Body Mass.

  Changes from WK0 in HES and BES scores are shown in Table ​Table1.1. No significant differences in the scores between the groups were noted at any time point. The total mood score from the POMS assessment is depicted in Figure ​Figure3.3. A significant difference between the groups was seen at WK4. Participants ingesting the supplement had significantly (p=0.006) greater decrease in total mood (a favorable response) than PLA. Similar patterns were also noted for fatigue (p=0.012) and confusion (0.009) at WK4 (see Table ​Table1).1). The only other significant difference noted was observed at WK8, where changes in tension was significantly (p=0.002) different between the groups.

  Table 1

  Changes from WK0 in hunger and satiety, binge eating and profile of mood states questionnaires

  		WK2	WK4	WK6	WK8
  Hunger and Satiety Scale	PLA	0.21±2.97	0.06±2.28	0.46±1.66	0.06±1.39
  	SUP	0.58±1.39	0.27±2.15	0.62±1.71	0.31±1.40
  Binge Eating Scale	PLA	-4.74±3.75	-6.53±4.87	-8.00±3.65	-7.06±4.99
  	SUP	-5.74±6.88	-5.71±6.68	-5.67±5.79	-6.53±7.15
  Profile of mood states
  Tension	PLA	1.79±5.90	1.35±3.97	2.62±7.70	0±2.47
  	SUP	-0.37±3.40	-2.07±4.08	-2.25±4.92	-3.20±2.76*
  Depression	PLA	2.84±8.17	0.88±3.35	3.23±11.58	0.59±4.30
  	SUP	-1.37±2.34	-1.86±2.93	-1.17±3.10	-1.07±3.45
  Anger	PLA	2.42±3.88	0.82±1.94	2.38±5.38	0.41±1.33
  	SUP	-0.53±3.36	-1.21±2.39	-0.58±3.40	-0.40±3.25
  Vigor	PLA	1.79±16.31	5.47±17.85	-0.38±15.88	2.59±14.62
  	SUP	3.47±12.75	8.21±11.37	4.17±8.48	7.80±9.79
  Fatigue	PLA	-0.47±8.58	0.35±4.40	2.85±10.64	-3.65±6.26
  	SUP	-4.84±11.35	-5.64±7.90*	-3.58±5.43	-5.27±6.30
  Confusion	PLA	3.37±8.22	1.06±5.03	3.69±10.73	-1.12±5.17
  	SUP	-1.58±5.27	-4.79±6.57*	-1.33±5.99	-2.27±55.11

  *=significant difference between groups.

  Figure 3

  
  
  

  

  Changes in total mood score. *=Significant difference (p=0.006) between groups.

  Discussion

  The results of this study suggest that a daily intake of 120mg NOPE and 105mg of EGCG for 4-weeks, can enhance compliance to a low caloric diet, total mood score, feelings of fatigue, and confusion, but does not alter body mass or body fat to any greater magnitude than placebo. However, these benefits were not maintained by week 8 of the study, where only feelings of tension were reduced in comparison to placebo. These findings contrast with Rondanelli et al., [17] in which sustained compliance and improvements in feelings of satiety, and severity of binge eating were observed for 8-weeks of study duration.

  It is possible that the method used to determine dietary compliance may have contributed to the differences between the studies. In the present investigation, compliance was defined as the ability to maintain the recommended low caloric diet. Rondonelli and colleagues defined compliance in terms of drop-out rate [17]. This may not entirely capture compliance, as approximately 72% of the participants, who did not drop out of the present study, were also unable to maintain the low caloric diet at one or more time points. This is supported by research investigating the psychological biases in self-reporting dietary habits in studies of caloric restraint [35,36]. Although a participant may appear to be following the experimental protocol by not withdrawing, many may seek either to provide the results that researchers expect (compliance) or to make their actions appear socially desirable [35,36]. Considering the lower daily caloric intakes of both groups, calculated from self-reported dietary recalls, greater reductions in body mass should have been observed. Regardless, differences in compliance through WK4 between the groups is likely attributable to the daily ingestion of NOPE. However, the 50mg per day lower dose used in this study compared to previous research [17], may have resulted in some degree of habituation following 4-weeks of supplementation, as previous investigations have noted dose-dependency [19,37].

  It has been suggested that NOPE may curb appetite by slowing down gastric emptying [38] and intestinal motility [39]. While the present study did not measure gastric emptying and intestinal mobility directly, the lack of significant differences in caloric intake or feelings of satiety observed may reflect no differences in gastric emptying and intestinal mobility. Although both groups experienced reductions in caloric intake, possible differences may have been confounded by the participants’ physical activity habits. During lower intensity exercise (< 70% VO2max), caloric intake may increase due to stimulated gastric emptying [40,41], while more strenuous exercise may delay gastric emptying [41], thus decreasing appetite. Considering that exercise patterns were similar between the groups, it is possible that the potential influence of NOPE on appetite [38,39] likely enhanced dietary compliance through WK4.

  The NOPE and EGCG combination has also been reported to reduce the severity of binge eating to a significantly greater degree than placebo [17]. While the present investigation noted decreases in BES scores for both groups, no significant differences were observed at any time point. However, baseline measurement scores suggest that neither group could be defined as binge eaters [34], which may imply that this proprietary supplement blend may be more effective in binge eaters. It is likely that reductions in BES scores in both groups may have also been the result of the combined diet and exercise program, as several studies have shown that a combination of diet and exercise may prevent the onset of binge eating in non-binge eaters [42,43].

  The present investigation does support previous findings that the NOPE-EGCG blend can significantly enhance mood [17]. Oral supplementation of EGCG has been suggested to impact central nervous system function in the brain [44-46] by affecting γ-aminobutyric acid receptor binding sites (GABAA) [47]. Since γ-Aminobutyric acid is the principal inhibitory neurotransmitter receptor system in the brain that regulates anxiety, EGCG ingestion may reduce anxiety. EGCG was been shown to reduce anxiety in mice [48,49], while regular green tea consumption lowers post-stress cortisol levels and increases subjective relaxation in humans [50]. Our findings show that mood, feelings of depression and confusion are all improved after four weeks of supplementation, with improvements in feelings of tension thereafter.

  Go to:

  Conclusion

  The results of this study indicate that a daily ingestion of a proprietary blend of 120mg of NOPE and 105mg of EGCG can enhance compliance to a low caloric diet, total mood score, feelings of fatigue, and confusion for 4-weeks, with improved feelings of tension thereafter. However, it does not have any significant effects on weight loss, changes in body composition, feelings of hunger, and binge eating in a group of healthy, overweight adults. The dose used in this study may have resulted in some degree of habituation following 4-weeks of supplementation.

  Go to:

  Abbreviations

  BES: Gormally Binge Eating Scale; BMI: Body Mass Index; CB1: Cannabinoid type 1 receptors; EGCG: Epigallocatechin gallate; HSS: Hunger and Satiety Scale; KCAL: Kilocalories; NOE: N-oleyl-ethanolamide; NOPE: N-oleoyl-phophatidyl-ethanolamine; PLA: Placebo; POMS: Profile of Mood States; SUP: Supplement; TMS: Total Mood Score.

  Go to:

  Competing interests

  The authors declare that they have no competing interests.

  Go to:

  Authors’ contributions

  JRH was the primary investigator and responsible for study design. GTM was responsible for protocol supervision, patient recruitment, registration, data collection, data entry. JRH and JRS performed the statistical analysis, JRH, GTM, JRS, and MSF participated in manuscript preparation. AJW, AMG, NSE, WPM and TCS assisted with data collection and data analysis. All authors read and approved the final manuscript.

  Go to:

  Acknowledgements

  The authors would like to thank a dedicated group of volunteers. This study was supported by a grant from Chemi Nutra, White Bear Lake, MN.

  Go to:

  References

  • Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010;303:235–241. doi: 10.1001/jama.2009.2014. [PubMed][Cross Ref]
  • National Center for Health Statistics. Brief. Hyattsville, MD; 2012. Health, United States, 2011.
  • Willett WC, Manson JE, Stampfer MJ, Colditz GA, Rosner B, Speizer FE, Hennekens CH. Weight, weight change, and coronary heart disease in women. Risk within the ’normal’ weight range. JAMA. 1995;273:461–465. doi: 10.1001/jama.1995.03520300035033. [PubMed][Cross Ref]
  • Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, Lang CC, Rumboldt Z, Onen CL, Lisheng L. et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case–control study. Lancet. 2005;366:1640–1649. doi: 10.1016/S0140-6736(05)67663-5. [PubMed] [Cross Ref]
  • Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 1995;122:481–486. [PubMed]
  • Ray CS, Sue DY, Bray G, Hansen JE, Wasserman K. Effects of obesity on respiratory function.Am Rev Respir Dis. 1983;128:501–506. [PubMed]
  • Janssen I. Morbidity and mortality risk associated with an overweight BMI in older men and women. Obesity (Silver Spring) 2007;15:1827–1840. doi: 10.1038/oby.2007.217. [PubMed][Cross Ref]
  • Andreou E, Philippou C, Papandreou D. Effects of an Intervention and Maintenance Weight Loss Diet with and without Exercise on Anthropometric Indices in Overweight and Obese Healthy Women. Ann Nutr Metab. 2011;59:187–192. doi: 10.1159/000334755. [PubMed][Cross Ref]
  • Villareal DT, Chode S, Parimi N, Sinacore DR, Hilton T, Armamento-Villareal R, Napoli N, Qualls C, Shah K. Weight loss, exercise, or both and physical function in obese older adults. N Engl J Med. 2011;364:1218–1229. doi: 10.1056/NEJMoa1008234. [PMC free article] [PubMed][Cross Ref]
  • Carels RA, Young KM, Coit C, Clayton AM, Spencer A, Hobbs M. Can following the caloric restriction recommendations from the Dietary Guidelines for Americans help individuals lose weight? Eat Behav. 2008;9:328–335. doi: 10.1016/j.eatbeh.2007.12.003. [PubMed] [Cross Ref]
  • Makris A, Foster GD. Dietary approaches to the treatment of obesity. Psychiatr Clin North Am.2011;34:813–827. doi: 10.1016/j.psc.2011.08.004. [PMC free article] [PubMed] [Cross Ref]
  • Arterburn D, Noel PH. Extracts from “Clinical Evidence”. Obesity. BMJ. 2001;322:1406–1409. doi: 10.1136/bmj.322.7299.1406. [PMC free article] [PubMed] [Cross Ref]
  • Barratt R, Frost G, O’Boyle A, Millward J, Truby H. Use of sibutramine to assist obese women with weight loss can be successful in dietitian-led clinics: another tool in the dietitian’s toolbox. J Hum Nutr Diet. 2008;21:248–255. doi: 10.1111/j.1365-277X.2008.00870.x. [PubMed][Cross Ref]
  • Ioannides-Demos LL, Proietto J, McNeil JJ. Pharmacotherapy for obesity. Drugs.2005;65:1391–1418. doi: 10.2165/00003495-200565100-00006. [PubMed] [Cross Ref]
  • Perrio MJ, Wilton LV, Shakir SA. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England. Obesity (Silver Spring) 2007;15:2712–2722. doi: 10.1038/oby.2007.323. [PubMed] [Cross Ref]
  • Manore MM. Dietary supplements for improving body composition and reducing body weight: where is the evidence? Int J Sport Nutr Exerc Metab. 2012;22:139–154. [PubMed]
  • Rondanelli M, Opizzi A, Solerte SB, Trotti R, Klersy C, Cazzola R. Administration of a dietary supplement (N-oleyl-phosphatidylethanolamine and epigallocatechin-3-gallate formula) enhances compliance with diet in healthy overweight subjects: a randomized controlled trial. Br J Nutr. 2009;101:457–464. [PubMed]
  • Williams CM, Kirkham TC. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 1999;143:315–317. doi: 10.1007/s002130050953.[PubMed] [Cross Ref]
  • Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodriguez De Fonseca F, Rosengarth A, Luecke H, Di Giacomo B, Tarzia G, Piomelli D. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature. 2003;425:90–93. doi: 10.1038/nature01921. [PubMed] [Cross Ref]
  • Overton HA, Babbs AJ, Doel SM, Fyfe MC, Gardner LS, Griffin G, Jackson HC, Procter MJ, Rasamison CM, Tang-Christensen M. et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab. 2006;3:167–175. doi: 10.1016/j.cmet.2006.02.004. [PubMed] [Cross Ref]
  • Chantre P, Lairon D. Recent findings of green tea extract AR25 (Exolise) and its activity for the treatment of obesity. Phytomedicine. 2002;9:3–8. doi: 10.1078/0944-7113-00078. [PubMed][Cross Ref]
  • Nagao T, Hase T, Tokimitsu I. A green tea extract high in catechins reduces body fat and cardiovascular risks in humans. Obesity (Silver Spring) 2007;15:1473–1483. doi: 10.1038/oby.2007.176. [PubMed] [Cross Ref]
  • Wang H, Wen Y, Du Y, Yan X, Guo H, Rycroft JA, Boon N, Kovacs EM, Mela DJ. Effects of catechin enriched green tea on body composition. Obesity (Silver Spring) 2010;18:773–779. doi: 10.1038/oby.2009.256. [PubMed] [Cross Ref]
  • Zhu BT, Shim JY, Nagai M, Bai HW. Molecular modelling study of the mechanism of high-potency inhibition of human catechol-O-methyltransferase by (-)-epigallocatechin-3-O-gallate.Xenobiotica. 2008;38:130–146. doi: 10.1080/00498250701744641. [PubMed] [Cross Ref]
  • Borchardt RT, Huber JA. Catechol O-methyltransferase. 5. Structure-activity relationships for inhibition by flavonoids. J Med Chem. 1975;18:120–122. doi: 10.1021/jm00235a030. [PubMed][Cross Ref]
  • Bose M, Lambert JD, Ju J, Reuhl KR, Shapses SA, Yang CS. The major green tea polyphenol, (-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice. J Nutr. 2008;138:1677–1683. [PMC free article] [PubMed]
  • Lonac MC, Richards JC, Schweder MM, Johnson TK, Bell C. Influence of short-term consumption of the caffeine-free, epigallocatechin-3-gallate supplement, Teavigo, on resting metabolism and the thermic effect of feeding. Obesity (Silver Spring) 2011;19:298–304. doi: 10.1038/oby.2010.181. [PubMed] [Cross Ref]
  • Broccali GBM, Pistolesi E, Cestaro B. N-oleoylphosphatidylethanolamine reduces food intake and body weight of dietary obese rats ameliorating their antioxidant status. Gazzeta Medica Italiana Archivo Per Le Scienze Mediche. 2005;164:101–107.
  • Board FN. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients) USA: The National Academies Press; 2002. (Book Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients)).
  • Hoffman J. Norms for fitness, performance, and health. USA: Human Kinetics, New Jersey; 2006.
  • Glickman SG, Marn CS, Supiano MA, Dengel DR. Validity and reliability of dual-energy X-ray absorptiometry for the assessment of abdominal adiposity. J Appl Physiol. 2004;97:509–514. doi: 10.1152/japplphysiol.01234.2003. [PubMed] [Cross Ref]
  • Katrina K, King N, Hayes D. Moving Away From Diets: Healing Eating Problems and Exercise Resistance. Texas, USA: Helm Publishing & Seminars; 2003.
  • McNair D, Lorr M, Droppleman LF. Profile of Mood States Manual. San Diego, CA: Educational and Industrial Testing Service; 1971. (Book Profile of Mood States Manual).
  • Gormally J, Black S, Daston S, Rardin D. The assessment of binge eating severity among obese persons. Addict Behav. 1982;7:47–55. doi: 10.1016/0306-4603(82)90024-7. [PubMed][Cross Ref]
  • Bingham SA, Cassidy A, Cole TJ, Welch A, Runswick SA, Black AE, Thurnham D, Bates C, Khaw KT, Key TJ. et al. Validation of weighed records and other methods of dietary assessment using the 24h urine nitrogen technique and other biological markers. Br J Nutr. 1995;73:531–550. doi: 10.1079/BJN19950057. [PubMed] [Cross Ref]
  • Hebert JR, Clemow L, Pbert L, Ockene IS, Ockene JK. Social Desirability Bias in Dietary Self-Report May Compromise the Validity of Dietary-Intake Measures. Int J Epidemiol.1995;24:389–398. doi: 10.1093/ije/24.2.389. [PubMed] [Cross Ref]
  • Ahern GP. Activation of TRPV1 by the satiety factor oleoylethanolamide. J Biol Chem.2003;278:30429–30434. doi: 10.1074/jbc.M305051200. [PubMed] [Cross Ref]
  • Aviello G, Matias I, Capasso R, Petrosino S, Borrelli F, Orlando P, Romano B, Capasso F, Di Marzo V, Izzo AA. Inhibitory effect of the anorexic compound oleoylethanolamide on gastric emptying in control and overweight mice. J Mol Med-Jmm. 2008;86:413–422. doi: 10.1007/s00109-008-0305-7. [PubMed] [Cross Ref]
  • Capasso R, Matias I, Lutz B, Borrelli F, Capasso F, Marsicano G, Mascolo N, Petrosino S, Monory K, Valenti M. et al. Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology. 2005;129:941–951. doi: 10.1053/j.gastro.2005.06.018. [PubMed][Cross Ref]
  • Thomas DM, Bouchard C, Church T, Slentz C, Kraus WE, Redman LM, Martin CK, Silva AM, Vossen M, Westerterp K, Heymsfield SB. Why do individuals not lose more weight from an exercise intervention at a defined dose? Obes Rev: An energy balance analysis; 2012.
  • King NA, Horner K, Hills AP, Byrne NM, Wood RE, Bryant E, Caudwell P, Finlayson G, Gibbons C, Hopkins M. et al. Exercise, appetite and weight management: understanding the compensatory responses in eating behaviour and how they contribute to variability in exercise-induced weight loss. Brit J Sport Med. 2012;46:315–322. doi: 10.1136/bjsm.2010.082495.[PubMed] [Cross Ref]
  • Wadden TA, Foster GD, Sarwer DB, Anderson DA, Gladis M, Sanderson RS, Letchak RV, Berkowitz RI, Phelan S. Dieting and the development of eating disorders in obese women: results of a randomized controlled trial. Am J Clin Nutr. 2004;80:560–568. [PubMed]
  • Sherwood NE, Jeffery RW, Wing RR. Binge status as a predictor of weight loss treatment outcome. Int J Obes Relat Metab Disord. 1999;23:485–493. doi: 10.1038/sj.ijo.0800846.[PubMed] [Cross Ref]
  • Brown AL, Lane J, Coverly J, Stocks J, Jackson S, Stephen A, Bluck L, Coward A, Hendrickx H. Effects of dietary supplementation with the green tea polyphenol epigallocatechin-3-gallate on insulin resistance and associated metabolic risk factors: randomized controlled trial. Br J Nutr.2009;101:886–894. doi: 10.1017/S0007114508047727. [PMC free article] [PubMed][Cross Ref]
  • Wightman EL, Haskell CF, Forster JS, Veasey RC, Kennedy DO. Epigallocatechin gallate, cerebral blood flow parameters, cognitive performance and mood in healthy humans: a double-blind, placebo-controlled, crossover investigation. Hum Psychopharmacol. 2012;27:177–186. doi: 10.1002/hup.1263. [PubMed] [Cross Ref]
  • Suganuma M, Okabe S, Oniyama M, Tada Y, Ito H, Fujiki H. Wide distribution of [3H](-)-epigallocatechin gallate, a cancer preventive tea polyphenol, in mouse tissue. Carcinogenesis.1998;19:1771–1776. doi: 10.1093/carcin/19.10.1771. [PubMed] [Cross Ref]
  • Paladini AC, Marder M, Viola H, Wolfman C, Wasowski C, Medina JH. Flavonoids and the central nervous system: from forgotten factors to potent anxiolytic compounds. J Pharm Pharmacol. 1999;51:519–526. [PubMed]
  • Adachi N, Tomonaga S, Tachibana T, Denbow DM, Furuse M. (-)-Epigallocatechin gallate attenuates acute stress responses through GABAergic system in the brain. Eur J Pharmacol.2006;531:171–175. doi: 10.1016/j.ejphar.2005.12.024. [PubMed] [Cross Ref]
  • Vignes M, Maurice T, Lante F, Nedjar M, Thethi K, Guiramand J, Recasens M. Anxiolytic properties of green tea polyphenol (-)-epigallocatechin gallate (EGCG) Brain Res.2006;1110:102–115. doi: 10.1016/j.brainres.2006.06.062. [PubMed] [Cross Ref]
  • Steptoe A, Gibson EL, Vuononvirta R, Williams ED, Hamer M, Rycroft JA, Erusalimsky JD, Wardle J. The effects of tea on psychophysiological stress responsivity and post-stress recovery: a randomised double-blind trial. Psychopharmacology (Berl) 2007;190:81–89. doi: 10.1007/s00213-006-0573-2. [PubMed] [Cross Ref]

影片介紹